Improved prediction of prognosis and therapy response for lung adenocarcinoma after identification of DNA-directed RNA polymerase-associated lncRNAs

[1]  Yue Xu,et al.  Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[2]  Jiong Hu,et al.  Characterization of DNA damage response deficiency in pancreatic cancer patients from China , 2021, Cancer communications.

[3]  Wen Li,et al.  Pyroptosis-Mediated Molecular Subtypes and Tumor Microenvironment Infiltration Characterization in Colon Cancer , 2021, Frontiers in Cell and Developmental Biology.

[4]  F. Lordick,et al.  Journal of Cancer Research and Clinical Oncology , 2021, Forum.

[5]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[6]  Yun Tang,et al.  The role of ferroptosis in breast cancer patients: a comprehensive analysis , 2021, Cell Death Discovery.

[7]  Xing Huang,et al.  Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development , 2021, Molecular Cancer.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  P. Cramer,et al.  Small-molecule inhibitors of human mitochondrial DNA transcription , 2020, Nature.

[10]  Xiaoli Liu,et al.  Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis , 2020, PloS one.

[11]  T. Vögeli,et al.  A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes , 2020, Cancers.

[12]  C. Gross,et al.  Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer , 2020, JAMA network open.

[13]  Chong Li,et al.  Non-coding RNA in bladder cancer. , 2020, Cancer letters.

[14]  Xiaochen Lu,et al.  Long noncoding RNAs AC026904.1 is essential for TGF-β-induced migration and epithelial-mesenchymal transition through functioning as an enhancer of Slug in lung cancer cells. , 2020, Environmental toxicology.

[15]  Peng Jiang,et al.  Large-scale public data reuse to model immunotherapy response and resistance , 2020, Genome Medicine.

[16]  Huaqin Pan,et al.  Long non‐coding RNA NORAD promotes the occurrence and development of non‐small cell lung cancer by adsorbing MiR‐656‐3p , 2019, Molecular genetics & genomic medicine.

[17]  Meiqin Wang,et al.  The POLR2E rs3787016 polymorphism is strongly associated with the risk of female breast and cervical cancer. , 2019, Pathology, research and practice.

[18]  Yujing Li,et al.  Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer , 2019, Nature Nanotechnology.

[19]  J. Humm,et al.  Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Xu Zhang,et al.  Correlation of T Cell Immunoglobulin and ITIM Domain (TIGIT) and Programmed Death 1 (PD-1) with Clinicopathological Characteristics of Renal Cell Carcinoma May Indicate Potential Targets for Treatment , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[21]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[22]  Kwok-Kin Wong,et al.  EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. , 2018, Cancer cell.

[23]  T. Ochiya,et al.  Emerging roles of long non‐coding RNA in cancer , 2018, Cancer science.

[24]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[25]  Hao Jiang,et al.  Cilia loss sensitizes cells to transformation by activating the mevalonate pathway , 2018, The Journal of experimental medicine.

[26]  M. Pujana,et al.  Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis , 2017, Nature Communications.

[27]  Weiqing Wang,et al.  The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing , 2017, Nature Communications.

[28]  Subbaya Subramanian,et al.  Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. , 2017, Cancer research.

[29]  H. Gu,et al.  Long noncoding RNAs POLR2E rs3787016 C/T and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer , 2015, Tumor Biology.

[30]  K. Ryan,et al.  Involvement of RNA Polymerase III in Immune Responses , 2015, Molecular and Cellular Biology.

[31]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[32]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[33]  Jing Liu,et al.  The Long Noncoding RNA HOTAIR Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma Cells via downregualtion of p21WAF1/CIP1 Expression , 2013, PloS one.

[34]  P. Cramer,et al.  Conservation between the RNA polymerase I, II, and III transcription initiation machineries. , 2012, Molecular cell.

[35]  J. Obata,et al.  Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. , 2011, Atherosclerosis.

[36]  Ami A. Shah,et al.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. , 2010, Arthritis and rheumatism.

[37]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[38]  Xiongbin Lu,et al.  Abstract A36: TP53 loss creates therapeutic vulnerability in colorectal cancer , 2017 .